Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study
Franco Locatelli(Bambino Gesù Children's Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Christine Rosko(Novartis (United States)), Katsuyoshi Koh(Saitama Children's Medical Center), Maura Faraci(Istituto Giannina Gaslini), Xuechan Li(Duke University), Anirudh Prahallad(Novartis (Switzerland)), Virginie Gandemer, Grace Cleary(Novartis (Ireland)), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Yoshiyuki Takahashi(Nagoya University), Hyoung Jin Kang(Seoul National University Children's Hospital), Annie St. Pierre(Novartis (Switzerland)), Bénedicte Bruno(Centre Hospitalier Universitaire de Lille), Fanny Rialland(Hôpital Mère-Enfant)
Cited by 24
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738